<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38381822</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Spontaneous, persistent, T cell-dependent IFN-&#x3b3; release in patients who progress to Long Covid.</ArticleTitle><Pagination><StartPage>eadi9379</StartPage><MedlinePgn>eadi9379</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eadi9379</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.adi9379</ELocationID><Abstract><AbstractText>After acute infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a proportion of patients experience persistent symptoms beyond 12 weeks, termed Long Covid. Understanding the mechanisms that cause this debilitating disease and identifying biomarkers for diagnostic, therapeutic, and monitoring purposes are urgently required. We detected persistently high levels of interferon-&#x3b3; (IFN-&#x3b3;) from peripheral blood mononuclear cells of patients with Long Covid using highly sensitive FluoroSpot assays. This IFN-&#x3b3; release was seen in the absence of ex vivo peptide stimulation and remains persistently elevated in patients with Long Covid, unlike the resolution seen in patients recovering from acute SARS-CoV-2 infection. The IFN-&#x3b3; release was CD8<sup>+</sup> T cell-mediated and dependent on antigen presentation by CD14<sup>+</sup> cells. Longitudinal follow-up of our study cohort showed that symptom improvement and resolution correlated with a decrease in IFN-&#x3b3; production to baseline levels. Our study highlights a potential mechanism underlying Long Covid, enabling the search for biomarkers and therapeutics in patients with Long Covid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishna</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-0919-2961</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Eleanor Y</ForeName><Initials>EY</Initials><Identifier Source="ORCID">0000-0002-4776-4820</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metaxaki</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4552-1622</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4230-9220</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mactavous</LastName><ForeName>Lenette</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7145-2934</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NIHR BioResource</CollectiveName><AffiliationInfo><Affiliation>NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-7035-8997</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doffinger</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-7774-8805</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Renal Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenneth G C</ForeName><Initials>KGC</Initials><Identifier Source="ORCID">0000-0003-3829-4326</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2616-9571</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheson</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-3318-1851</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHS Blood and Transplant, Cambridge CB2 0PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehner</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0001-9383-1054</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sithole</LastName><ForeName>Nyaradzai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8020-223X</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-8548-5729</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V011561/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W018861/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="Y">Interferon-gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38381822</ArticleId><ArticleId IdType="pmc">PMC10881041</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adi9379</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scherlinger M., Felten R., Gallais F., Nazon C., Chatelus E., Pijnenburg L., Mengin A., Gras A., Vidailhet P., Arnould-Michel R., Bibi-Triki S., Carapito R., Trouillet-Assant S., Perret M., Belot A., Bahram S., Arnaud L., Gottenberg J. E., Fafi-Kremer S., Sibilia J., Refining &#x201c;long-COVID&#x201d; by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect. Dis. Ther. 10, 1747&#x2013;1763 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., Luo J., Huang Z., Tu S., Zhao Y., Chen L., Xu D., Li Y., Li C., Peng L., Li Y., Xie W., Cui D., Shang L., Fan G., Xu J., Wang G., Wang Y., Zhong J., Wang C., Wang J., Zhang D., Cao B., 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 397, 220&#x2013;232 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A., Post-covid syndrome in individuals admitted to hospital with covid-19: Retrospective cohort study. BMJ 372, n693 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Madhavan M. V., Sehgal K., Nair N., Mahajan S., Sehrawat T. S., Bikdeli B., Ahluwalia N., Ausiello J. C., Wan E. Y., Freedberg D. E., Kirtane A. J., Parikh S. A., Maurer M. S., Nordvig A. S., Accili D., Bathon J. M., Mohan S., Bauer K. A., Leon M. B., Krumholz H. M., Uriel N., Mehra M. R., Elkind M. S. V., Stone G. W., Schwartz A., Ho D. D., Bilezikian J. P., Landry D. W., Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017&#x2013;1032 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E. J., Williams D. M., Walker A. J., Mitchell R. E., Niedzwiedz C. L., Yang T. C., Huggins C. F., Kwong A. S. F., Silverwood R. J., di Gessa G., Bowyer R. C. E., Northstone K., Hou B., Green M. J., Dodgeon B., Doores K. J., Duncan E. L., Williams F. M. K., OpenSAFELY Collaborative, Walker A. J., MacKenna B., Inglesby P., Rentsch C. T., Curtis H. J., Morton C. E., Morley J., Mehrkar A., Bacon S., Hickman G., Bates C., Croker R., Evans D., Ward T., Cockburn J., Davy S., Bhaskaran K., Schultze A., Williamson E. J., Hulme W. J., McDonald H. I., Tomlinson L., Mathur R., Eggo R. M., Wing K., Wong A. Y. S., Forbes H., Tazare J., Parry J., Hester F., Harper S., Douglas I. J., Evans S. J. W., Smeeth L., Goldacre B., Steptoe A., Porteous D. J., McEachan R. R. C., Tomlinson L., Goldacre B., Patalay P., Ploubidis G. B., Katikireddi S. V., Tilling K., Rentsch C. T., Timpson N. J., Chaturvedi N., Steves C. J., Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 13, 3528 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J. K., Franko N. M., McCulloch D. J., McDonald D., Magedson A., Wolf C. R., Chu H. Y., Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw. Open 4, e210830&#x2013;e210830 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M. S., Kristiansen M. F., Hanusson K. D., Danielsen M. E., Steig B. &#xc1;., Gaini S., Str&#xf8;m M., Weihe P., Long COVID in the Faroe Islands-A longitudinal study among non-hospitalized patients. Clin. Infect. Dis. 73, e4058&#x2013;e4063 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne S. M., Stromberg S., Baxter B. A., Webb T. L., Dutt T. S., Berry K., Tipton M., Haberman J., Massey B. R., McFann K., Alnachoukati O., Zier L., Heacock T., Ebel G. D., Henao-Tamayo M., Dunn J., Ryan E. P., A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect. Dis. 21, 677 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276222</ArticleId><ArticleId IdType="pubmed">34256735</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B., Wills M., Sithole N., Long COVID: What is known and what gaps need to be addressed. Br. Med. Bull. 147, 6&#x2013;19 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10502447</ArticleId><ArticleId IdType="pubmed">37434326</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dowds J., O&#x2019;Brien K., Sheill G., Dyer A. H., O&#x2019;Kelly B., Hynes J. P., Mooney A., Dunne J., Ni Cheallaigh C., O&#x2019;Farrelly C., Bourke N. M., Conlon N., Martin-Loeches I., Bergin C., Nadarajan P., Bannan C., Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. Ann. Am. Thorac. Soc. 18, 997&#x2013;1003 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W. D., Sherwood O., Banerjee A., Van der Togt V., Hishmeh L., Rossman J., The impact of COVID vaccination on symptoms of Long COVID. An international survey of people with lived experience of Long COVID. Vaccines 10, 652 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B. A., Metaxaki M., Wills M. R., Sithole N., Reduced incidence of long coronavirus disease referrals to the Cambridge University teaching hospital long coronavirus disease clinic. Clin. Infect. Dis. 76, 738&#x2013;740 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384550</ArticleId><ArticleId IdType="pubmed">35913432</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B. A., Lim E. Y., Mactavous L., NIHR BioResource Team, Lyons P. A., Doffinger R., Bradley J. R., Smith K. G. C., Sinclair J., Matheson N. J., Lehner P. J., Wills M. R., Sithole N., Evidence of previous SARS-CoV-2 infection in seronegative patients with Long COVID. EBioMedicine 81, 104129 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="pubmed">35772216</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S. E., Sedikides G. X., Okecha G., Poole E. L., Sinclair J. H., Wills M. R., Latent cytomegalovirus (CMV) infection does not detrimentally alter T cell responses in the healthy old, but increased latent CMV carriage is related to expanded CMV-specific T cells. Front. Immunol. 8, 733 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5483450</ArticleId><ArticleId IdType="pubmed">28694811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., Hanson A. L., Kotagiri P., Dunmore B. J., Ruffieux H., de Sa A., Huhn O., Morgan M. D., Gerber P. P., Wills M. R., Baker S., Calero-Nieto F. J., Doffinger R., Dougan G., Elmer A., Goodfellow I. G., Gupta R. K., Hosmillo M., Hunter K., Kingston N., Lehner P. J., Matheson N. J., Nicholson J. K., Petrunkina A. M., Richardson S., Saunders C., Thaventhiran J. E. D., Toonen E. J. M., Weekes M. P., Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, G&#xf6;ttgens B., Toshner M., Hess C., Bradley J. R., Lyons P. A., Smith K. G. C., Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54, 1257&#x2013;1275.e8 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J. K., Sarkar S., Fram T. R., Boppana S., Sterrett S., Qin K., Bansal A., Long D. M., Sabbaj S., Kobie J. J., Goepfert P. A., Erdmann N., Duration of post&#x2013;COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI insight 6, e151544 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C. H., Murray B., Varsavsky T., Graham M. S., Penfold R. S., Bowyer R. C., Pujol J. C., Klaser K., Antonelli M., Canas L. S., Molteni E., Modat M., Jorge Cardoso M., May A., Ganesh S., Davies R., Nguyen L. H., Drew D. A., Astley C. M., Joshi A. D., Merino J., Tsereteli N., Fall T., Gomez M. F., Duncan E. L., Menni C., Williams F. M. K., Franks P. W., Chan A. T., Wolf J., Ourselin S., Spector T., Steves C. J., Attributes and predictors of Long COVID. Nat. Med. 27, 626&#x2013;631 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J. R., Husain M., Harrison P. J., Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D. R., Wilson D. B., Howe A., Munier C. M. L., Patel S. K., Juno J. A., Burrell L. M., Kent S. J., Dore G. J., Kelleher A. D., Matthews G. V., Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210&#x2013;216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller C. H. T., Maher S. G., Young H. A., Clinical use of interferon-&#x3b3;. Ann. N. Y. Acad. Sci. 1182, 69&#x2013;79 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6574079</ArticleId><ArticleId IdType="pubmed">20074276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto E. F., Andrade C., Interferon-related depression: A primer on mechanisms, treatment, and prevention of a common clinical problem. Curr. Neuropharmacol. 14, 743&#x2013;748 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050402</ArticleId><ArticleId IdType="pubmed">26733280</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D., Liu G., Gack M. U., Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. 20, 397&#x2013;398 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative , Mapping the human genetic architecture of COVID-19. Nature 600, 472&#x2013;477 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Padilla S., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J. A., Agull&#xf3; V., Andreo M., Ruiz S., Galiana A., Guti&#xe9;rrez F., Masi&#xe1; M., Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: A longitudinal study. J. Clin. Immunol. 41, 1490&#x2013;1501 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B. K., Francisco E. B., Yogendra R., Long E., Pise A., Rodrigues H., Hall E., Herrera M., Parikh P., Guevara-Coto J., Triche T. J., Scott P., Hekmati S., Maglinte D., Chang X., Mora-Rodr&#xed;guez R. A., Mora J., Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front. Immunol. 12, 746021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmo A., Pereira-Vaz J., Mota V., Mendes A., Morais C., da Silva A. C., Camilo E., Pinto C. S., Cunha E., Pereira J., Coucelo M., Martinho P., Correia L., Marques G., Ara&#xfa;jo L., Rodrigues F., Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. J. Med. Virol. 92, 2227&#x2013;2231 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301002</ArticleId><ArticleId IdType="pubmed">32484958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E. Y., Mao T., Klein J., Dai Y., Huck J. D., Jaycox J. R., Liu F., Zhou T., Israelow B., Wong P., Coppi A., Lucas C., Silva J., Oh J. E., Song E., Perotti E. S., Zheng N. S., Fischer S., Campbell M., Fournier J. B., Wyllie A. L., Vogels C. B. F., Ott I. M., Kalinich C. C., Petrone M. E., Watkins A. E., Yale IMPACT Team, Obaid A., Moore A. J., Casanovas-Massana A., Lu-Culligan A., Nelson A., Nunez A., Martin A., Geng B., Odio C. D., Harden C. A., Todeasa C., Jensen C., Kim D., McDonald D., Shepard D., Courchaine E., White E. B., Silva E., Kudo E., DeIuliis G., Rahming H., Park H. J., Matos I., Nouws J., Valdez J., Lim J., Rose K. A., Anastasio K., Brower K., Glick L., Sharma L., Sewanan L., Knaggs L., Minasyan M., Batsu M., Kuang M., Nakahata M., Linehan M., Askenase M. H., Simonov M., Smolgovsky M., Sonnert N., Naushad N., Vijayakumar P., Martinello R., Datta R., Handoko R., Bermejo S., Prophet S., Bickerton S., Velazquez S., Rice T., Khoury-Hanold W., Peng X., Yang Y., Cao Y., Strong Y., dela Cruz C., Farhadian S. F., Schulz W. L., Ma S., Grubaugh N. D., Ko A. I., Iwasaki A., Ring A. M., Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283&#x2013;288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M. V., McGroder C., Stevens J. S., Cook J. R., Nordvig A. S., Shalev D., Sehrawat T. S., Ahluwalia N., Bikdeli B., Dietz D., der-Nigoghossian C., Liyanage-Don N., Rosner G. F., Bernstein E. J., Mohan S., Beckley A. A., Seres D. S., Choueiri T. K., Uriel N., Ausiello J. C., Accili D., Freedberg D. E., Baldwin M., Schwartz A., Brodie D., Garcia C. K., Elkind M. S. V., Connors J. M., Bilezikian J. P., Landry D. W., Wan E. Y., Post-acute COVID-19 syndrome. Nat. Med. 27, 601&#x2013;615 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D. G., Ng R. H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., Kornilov S. A., Scherler K., Pavlovitch-Bedzyk A. J., Dong S., Lausted C., Lee I., Fallen S., Dai C. L., Baloni P., Smith B., Duvvuri V. R., Anderson K. G., Li J., Yang F., Duncombe C. J., McCulloch D., Rostomily C., Troisch P., Zhou J., Mackay S., DeGottardi Q., May D. H., Taniguchi R., Gittelman R. M., Klinger M., Snyder T. M., Roper R., Wojciechowska G., Murray K., Edmark R., Evans S., Jones L., Zhou Y., Rowen L., Liu R., Chour W., Algren H. A., Berrington W. R., Wallick J. A., Cochran R. A., Micikas M. E., ISB-Swedish COVID-19 Biobanking Unit, Wrin T., Petropoulos C. J., Cole H. R., Fischer T. D., Wei W., Hoon D. S. B., Price N. D., Subramanian N., Hill J. A., Hadlock J., Magis A. T., Ribas A., Lanier L. L., Boyd S. D., Bluestone J. A., Chu H., Hood L., Gottardo R., Greenberg P. D., Davis M. M., Goldman J. D., Heath J. R., Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895.e20 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J. R., Dhodapkar R. M., Lu P., Gehlhausen J. R., Tabachnikova A., Greene K., Tabacof L., Malik A. A., Monteiro V. S., Silva J., Kamath K., Zhang M., Dhal A., Ott I. M., Valle G., Pe&#xf1;a-Hern&#xe1;ndez M., Mao T., Bhattacharjee B., Takahashi T., Lucas C., Song E., Carthy D. M., Breyman E., Tosto-Mancuso J., Dai Y., Perotti E., Akduman K., Tzeng T. J., Xu L., Geraghty A. C., Monje M., Yildirim I., Shon J., Medzhitov R., Lutchmansingh D., Possick J. D., Kaminski N., Omer S. B., Krumholz H. M., Guan L., Dela Cruz C. S., van Dijk D., Ring A. M., Putrino D., Iwasaki A., Distinguishing features of Long COVID identified through immune profiling. Nature 623, 139&#x2013;148 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M. J., Deveau T. M., Munter S. E., Ryder D., Buck A., Beck-Engeser G., Chan F., Lu S., Goldberg S. A., Hoh R., Tai V., Torres L., Iyer N. S., Deswal M., Ngo L. H., Buitrago M., Rodriguez A., Chen J. Y., Yee B. C., Chenna A., Winslow J. W., Petropoulos C. J., Deitchman A. N., Hellmuth J., Spinelli M. A., Durstenfeld M. S., Hsue P. Y., Kelly J. D., Martin J. N., Deeks S. G., Hunt P. W., Henrich T. J., Chronic viral coinfections differentially affect the likelihood of developing Long COVID. J. Clin. Invest. 133, e163669 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., Vlok M., Turner S., Venter C., Laubscher G. J., Kell D. B., Pretorius E., Proteomics of fibrin amyloid microclots in Long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol. 21, 190 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R., Riste L., Hann M., Walther A., Mukherjee A., Heald A., Into the looking glass: Post-viral syndrome post COVID-19. Med. Hypotheses 144, 110055&#x2013;110055 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320866</ArticleId><ArticleId IdType="pubmed">32758891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C., Samir J., Pirozyan M. R., Adikari T. N., Gupta M., Leung P., Hughes B., van der Byl W., Rizzetto S., Elthala A., Keoshkerian E., Palgen J. L., Peters T., Nguyen T. H. O., Louie R., Kedzierska K., Gaudieri S., Bull R. A., Lloyd A. R., Luciani F., Identification of human progenitors of exhausted CD8+ T cells associated with elevated IFN-&#x3b3; response in early phase of viral infection. Nat. Commun. 13, 7543 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729230</ArticleId><ArticleId IdType="pubmed">36477661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Patel K., Greenwood D. C., Halpin S., Lewthwaite P., Salawu A., Eyre L., Breen A., O&#x2019;Connor R., Jones A., Sivan M., Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J. Rehabil. Med. 52, jrm00063 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui D., Joynt G. M., Wong K. T., Gomersall C. D., Li T. S., Antonio G., Ko F. W., Chan M. C., Chan D. P., Tong M. W., Rainer T. H., Ahuja A. T., Cockram C. S., Sung J. J., Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 60, 401&#x2013;409 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1758905</ArticleId><ArticleId IdType="pubmed">15860716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam M. H.-B., Wing Y.-K., Yu M. W.-M., Leung C.-M., Ma R. C. W., Kong A. P. S., So W. Y., Fong S. Y.-Y., Lam S.-P., Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: Long-term follow-up. Arch. Intern. Med. 169, 2142&#x2013;2147 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A. M., Wong J. G. W. S., McAlonan G. M., Cheung V., Cheung C., Sham P. C., Chu C. M., Wong P. C., Tsang K. W. T., Chua S. E., Stress and psychological distress among SARS survivors 1 year after the outbreak. Can. J. Psychiatry 52, 233&#x2013;240 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17500304</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H., Patcai J., Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 11, 37 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K. C., Ng A. W., Lee L. S., Kaw G., Kwek S. K., Leow M. K., Earnest A., Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur. Respir. J. 24, 436&#x2013;442 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15358703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S. H., Shin H. S., Park H. Y., Kim J. L., Lee J. J., Lee H., Won S. D., Han W., Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in Middle East respiratory syndrome survivors. Psychiatry Investig. 16, 59&#x2013;64 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354037</ArticleId><ArticleId IdType="pubmed">30605995</ArticleId></ArticleIdList></Reference><Reference><Citation>Seet R. C. S., Quek A. M. L., Lim E. C. H., Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol. 38, 1&#x2013;6 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17137834</ArticleId></ArticleIdList></Reference><Reference><Citation>White P. D., Thomas J. M., Kangro H. O., Bruce-Jones W. D. A., Amess J., Crawford D. H., Grover S. A., Clare A. W., Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 358, 1946&#x2013;1954 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11747919</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchwald D. S., Rea T. D., Katon W. J., Russo J. E., Ashley R. L., Acute infectious mononucleosis: Characteristics of patients who report failure to recover. Am. J. Med. 109, 531&#x2013;537 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11063953</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen I., Thomas J., Hamilton W., White P., Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. Qjm 99, 49&#x2013;55 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16330509</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz B. Z., Shiraishi Y., Mears C. J., Binns H. J., Taylor R., Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 124, 189&#x2013;193 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756827</ArticleId><ArticleId IdType="pubmed">19564299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hives L., Bradley A., Richards J., Sutton C., Selfe J., Basu B., Maguire K., Sumner G., Gaber T., Mukherjee A., Perrin R. N., Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ open 7, e017521 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5695376</ArticleId><ArticleId IdType="pubmed">29133321</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X., Qu K., Ciazynska K. A., Hosmillo M., Carter A. P., Ebrahimi S., Ke Z., Scheres S. H. W., Bergamaschi L., Grice G. L., Zhang Y., The CITIID-NIHR COVID-19 BioResource Collaboration, Bradley J., Lyons P. A., Smith K. G. C., Toshner M., Elmer A., Ribeiro C., Kourampa J., Jose S., Kennet J., Rowlands J., Meadows A., O&#x2019;Brien C., Rastall R., Crucusio C., Hewitt S., Price J., Calder J., Canna L., Bucke A., Tordesillas H., Harris J., Ruffolo V., Domingo J., Graves B., Butcher H., Caputo D., le Gresley E., Dunmore B. J., Martin J., Legchenko E., Treacy C., Huang C., Wood J., Sutcliffe R., Hodgson J., Shih J., Graf S., Tong Z., Mescia F., Tilly T., O&#x2019;Donnell C., Hunter K., Pointon L., Pond N., Wylot M., Jones E., Fawke S., Bullman B., Bergamaschi L., Turner L., Jarvis I., Omarjee O., de Sa A., Marsden J., Betancourt A., Perera M., Epping M., Richoz N., Bower G., Sharma R., Nice F., Huhn O., Stark H., Walker N., Stirrups K., Ovington N., Dewhust E., Li E., Papadia S., Nathan J. A., Baker S., James L. C., Baxendale H. E., Goodfellow I., Doffinger R., Briggs J. A. G., A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934&#x2013;941 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116388</ArticleId><ArticleId IdType="pubmed">32737467</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadlbauer D., Amanat F., Chromikova V., Jiang K., Strohmeier S., Arunkumar G. A., Tan J., Bhavsar D., Capuano C., Kirkpatrick E., Meade P., Brito R. N., Teo C., McMahon M., Simon V., Krammer F., SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235504</ArticleId><ArticleId IdType="pubmed">32302069</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D. A., Ferreira I. A. T. M., Kotagiri P., Datir R. P., Lim E. Y., Touizer E., Meng B., Abdullahi A., CITIID-NIHR Bio Resource COVID- Collaboration, Elmer A., Kingston N., Graves B., Gresley E. L., Caputo D., Bergamaschi L., Smith K. G. C., Bradley J. R., Ceron-Gutierrez L., Cortes-Acevedo P., Barcenas-Morales G., Linterman M. A., Coy L. E. M., Davis C., Thomson E., Lyons P. A., Kinney E. M., Doffinger R., Wills M., Gupta R. K., Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417&#x2013;422 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley-McBain T., Heit A., De Rosa S. C., McElrath M. J., Andersen-Nissen E., Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. J. Immunol. Methods 411, 23&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171197</ArticleId><ArticleId IdType="pubmed">24925805</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies E. L., Noor M., Lim E. Y., Houldcroft C. J., Okecha G., Atkinson C., Reeves M. B., Jackson S. E., Wills M. R., HCMV carriage in the elderly diminishes anti-viral functionality of the adaptive immune response resulting in virus replication at peripheral sites. Front. Immunol. 13, 1083230 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9797693</ArticleId><ArticleId IdType="pubmed">36591233</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S. E., Sedikides G. X., Romashova V., Okecha G., Remmerswaal E. B. M., Bemelman F. J., Sinclair J. H., Wills M. R., IL-10-Secreting CD8+ T Cells Specific for Human Cytomegalovirus (HCMV): Generation, Maintenance and Phenotype. Pathogens 11, 1530 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9781655</ArticleId><ArticleId IdType="pubmed">36558866</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S. E., Sedikides G. X., Mason G. M., Okecha G., Wills M. R., Human Cytomegalovirus (HCMV)-Specific CD4+ T Cells Are Polyfunctional and Can Respond to HCMV-Infected Dendritic Cells In Vitro. J. Virol. 91, e02128-16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331818</ArticleId><ArticleId IdType="pubmed">28053099</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>